BioCentury
ARTICLE | Company News

Vertex nears Orkambi reimbursement agreement with Australia

August 17, 2018 6:59 PM UTC

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recommended in July that the government subsidize the price of Orkambi lumacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). The drug is approved to treat cystic fibrosis in patients ages six and older who have two copies of the F508del mutation.

The committee recommended Orkambi be listed on the country's Pharmaceutical Benefits Scheme (PBS) schedule under a Managed Access Program, which requires Vertex to provide long-term data showing the drug's benefits are sustained for at least four years...